JP2009511026A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009511026A5 JP2009511026A5 JP2008534895A JP2008534895A JP2009511026A5 JP 2009511026 A5 JP2009511026 A5 JP 2009511026A5 JP 2008534895 A JP2008534895 A JP 2008534895A JP 2008534895 A JP2008534895 A JP 2008534895A JP 2009511026 A5 JP2009511026 A5 JP 2009511026A5
- Authority
- JP
- Japan
- Prior art keywords
- myocardial infarction
- determined
- group
- cells
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 claims 30
- 208000010125 myocardial infarction Diseases 0.000 claims 9
- 101000881650 Homo sapiens Prolyl hydroxylase EGLN2 Proteins 0.000 claims 7
- 208000029078 coronary artery disease Diseases 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 208000001435 Thromboembolism Diseases 0.000 claims 5
- 208000006011 Stroke Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 102000048660 human EGLN2 Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 239000000523 sample Substances 0.000 claims 4
- 230000009424 thromboembolic effect Effects 0.000 claims 4
- 238000009396 hybridization Methods 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 102100037248 Prolyl hydroxylase EGLN2 Human genes 0.000 claims 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 2
- 230000003321 amplification Effects 0.000 claims 2
- 238000004458 analytical method Methods 0.000 claims 2
- 210000001124 body fluid Anatomy 0.000 claims 2
- 239000010839 body fluid Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 238000010195 expression analysis Methods 0.000 claims 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims 2
- 238000012163 sequencing technique Methods 0.000 claims 2
- 238000010998 test method Methods 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 claims 1
- 108020003215 DNA Probes Proteins 0.000 claims 1
- 238000000018 DNA microarray Methods 0.000 claims 1
- 239000003298 DNA probe Substances 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 206010060860 Neurological symptom Diseases 0.000 claims 1
- 238000000636 Northern blotting Methods 0.000 claims 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 238000002105 Southern blotting Methods 0.000 claims 1
- 210000004102 animal cell Anatomy 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 239000013611 chromosomal DNA Substances 0.000 claims 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 239000002853 nucleic acid probe Substances 0.000 claims 1
- 238000003203 nucleic acid sequencing method Methods 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 238000012175 pyrosequencing Methods 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims 1
- 229940104230 thymidine Drugs 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 229940035893 uracil Drugs 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005048899A DE102005048899A1 (de) | 2005-10-12 | 2005-10-12 | Verfahren zur Diagnose thromboembolischer Erkrankungen und koronarer Herzerkrankungen |
| PCT/EP2006/009517 WO2007042165A1 (de) | 2005-10-12 | 2006-09-30 | Verfahren zur diagnose thromboembolischer erkrankungen und koronarer herzerkrankungen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009511026A JP2009511026A (ja) | 2009-03-19 |
| JP2009511026A5 true JP2009511026A5 (enExample) | 2009-11-12 |
Family
ID=37684083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008534895A Abandoned JP2009511026A (ja) | 2005-10-12 | 2006-09-30 | 血栓塞栓性及び冠状動脈性心疾患の診断方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20090197774A1 (enExample) |
| EP (1) | EP1937839B1 (enExample) |
| JP (1) | JP2009511026A (enExample) |
| KR (1) | KR20080052662A (enExample) |
| CN (1) | CN101287846A (enExample) |
| AR (1) | AR056125A1 (enExample) |
| AT (1) | ATE525481T1 (enExample) |
| AU (1) | AU2006301578B9 (enExample) |
| BR (1) | BRPI0617341A2 (enExample) |
| CA (1) | CA2625698A1 (enExample) |
| DE (1) | DE102005048899A1 (enExample) |
| IL (1) | IL190585A (enExample) |
| TW (1) | TW200734638A (enExample) |
| WO (1) | WO2007042165A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005048898A1 (de) * | 2005-10-12 | 2007-04-19 | Sanofi-Aventis Deutschland Gmbh | EGLN2-Varianten und ihre Verwendung bei der Vorbeugung oder Behandlung thromboembolischer Erkrankungen und koronarer Herzerkrankungen |
| EP2311981B1 (en) | 2007-05-01 | 2014-09-17 | The Regents of The University of California | Methods for diagnosing ischemia |
| US20120015904A1 (en) * | 2010-07-14 | 2012-01-19 | Regents Of The University Of California | Biomarkers for diagnosis of transient ischemic attacks |
| CA2804802C (en) | 2010-07-15 | 2023-03-07 | The Regents Of The University Of California | Biomarkers for diagnosis of stroke and its causes |
| US20120316076A1 (en) | 2011-03-04 | 2012-12-13 | The Regents Of The University Of California | Biomarkers for the diagnosis of lacunar stroke |
| CA2856461C (en) * | 2011-12-01 | 2020-08-18 | F. Hoffmann-La Roche Ag | Nt-proanp and nt-probnp for the diagnosis of stroke |
| WO2013103781A1 (en) | 2012-01-07 | 2013-07-11 | The Regents Of The University Of California | Biomarkers for diagnosing ischemia |
| KR101939778B1 (ko) | 2012-07-27 | 2019-01-18 | 삼성전자주식회사 | 필요 혈류량 결정 방법 및 장치, 혈류 영상 생성 방법 및 장치, 심근 관류 영상 처리 방법 및 장치 |
| CN119846215B (zh) * | 2025-01-22 | 2025-07-11 | 广西医科大学附属肿瘤医院 | Egln1乳酸化作为靶点在制备肿瘤诊断试剂盒或治疗药物中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2474630B1 (en) * | 2002-12-20 | 2016-04-27 | Celera Corporation | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof |
| CA2510895A1 (en) * | 2002-12-20 | 2004-07-15 | Applera Corporation | Genetic polymorphisms associated with stenosis, methods of detection and uses thereof |
-
2005
- 2005-10-12 DE DE102005048899A patent/DE102005048899A1/de not_active Withdrawn
-
2006
- 2006-09-30 US US12/089,624 patent/US20090197774A1/en not_active Abandoned
- 2006-09-30 JP JP2008534895A patent/JP2009511026A/ja not_active Abandoned
- 2006-09-30 WO PCT/EP2006/009517 patent/WO2007042165A1/de not_active Ceased
- 2006-09-30 BR BRPI0617341-1A patent/BRPI0617341A2/pt not_active Application Discontinuation
- 2006-09-30 CA CA002625698A patent/CA2625698A1/en not_active Withdrawn
- 2006-09-30 EP EP06792341A patent/EP1937839B1/de not_active Not-in-force
- 2006-09-30 AT AT06792341T patent/ATE525481T1/de active
- 2006-09-30 KR KR1020087008790A patent/KR20080052662A/ko not_active Withdrawn
- 2006-09-30 AU AU2006301578A patent/AU2006301578B9/en not_active Withdrawn - After Issue
- 2006-09-30 CN CNA2006800376009A patent/CN101287846A/zh active Pending
- 2006-10-05 TW TW095136992A patent/TW200734638A/zh unknown
- 2006-10-10 AR ARP060104446A patent/AR056125A1/es unknown
-
2008
- 2008-04-02 IL IL190585A patent/IL190585A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA020795B1 (ru) | Генетические маркеры, ассоциированные с ответом на интерферон-альфа | |
| CN110541025B (zh) | 杜氏肌营养不良基因缺陷的检测方法、引物组合物及试剂盒 | |
| JP6447829B2 (ja) | Ｒｎａ修飾の簡易検出法、及び該検出法を用いた２型糖尿病の検査方法 | |
| JP2009511026A5 (enExample) | ||
| CN112501257A (zh) | 一种基于核酸自组装无酶催化的circRNA活细胞内成像的可视化传感器 | |
| EP1411120A4 (en) | DNA ARRAYS FOR MEASURING SENSITIVITY AGAINST AN ANTICREMENT | |
| KR101476781B1 (ko) | 결핵 진단용 바이오마커 마이크로 rna | |
| CN105586406A (zh) | Adrb1，grk5基因多态性的检测方法 | |
| CN108977443B (zh) | 一种表达动脉粥样硬化炎症活动的环状rna及其应用 | |
| CN107177676A (zh) | 长链非编码rna nonhsat113026用于肾癌诊断分子标志物的用途 | |
| KR102003835B1 (ko) | 섬유증 감수성 il22ra2 유전자 및 이의 용도 | |
| CN102787161A (zh) | 一种检测结核分枝杆菌方法及其专用引物 | |
| JP2009511026A (ja) | 血栓塞栓性及び冠状動脈性心疾患の診断方法 | |
| JP2013176383A (ja) | 遺伝子発現解析ツール | |
| CN111411152A (zh) | 人源环状rna在制备心脏疾病相关产品中的应用 | |
| Jun et al. | The protective effect of ischemic preconditioning associated with altered gene expression profiles in rat lung after reperfusion | |
| CN104404044B (zh) | 与心肌梗死易感相关的anril基因外显子区单核苷酸多态位点的检测方法及其应用 | |
| CN111378739B (zh) | 一种检测cyp2c19基因多态性的检测位点、引物组合物及其应用 | |
| CN109913481B (zh) | PIK3CA基因g.179224821G＞A突变及其在乳腺癌辅助诊断中的应用 | |
| CN109609620B (zh) | 用于辅助诊断血行播散型肺结核的试剂盒 | |
| CN115992232B (zh) | lncRNAGACAT2在制备预测肾透明细胞癌预后产品中的应用 | |
| CN201390750Y (zh) | 膀胱癌遗传检测试剂盒 | |
| CN108384848A (zh) | 血清中circ_0021132作为深静脉血栓形成诊断标志物的应用 | |
| KR20180044153A (ko) | 바이오마커 마이크로rna-144를 이용한 결핵 진단용 조성물 | |
| CN105316350A (zh) | 结核分枝杆菌EmbB突变基因及其用途 |